Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

BACKGROUND: The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. METHODS: Peripheral blood mononuclear cells from healthy donors were incubated with different JAKis, levels of phospho...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: McInnes, Iain B., Byers, Nicole L., Higgs, Richard E., Lee, Jonathan, Macias, William L., Na, Songqing, Ortmann, Robert A., Rocha, Guilherme, Rooney, Terence P., Wehrman, Thomas, Zhang, Xin, Zuckerman, Steven H., Taylor, Peter C.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6679539/
https://ncbi.nlm.nih.gov/pubmed/31375130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1964-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires